This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ICON Announces Appointment Of Cathrin Petty To Board Of Directors

ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Cathrin Petty as a non-executive Director. Cathrin was appointed unanimously by ICON’s board of directors and, in accordance with the company’s Articles of Association, will stand for re-election by ICON’s shareholders at the Company’s next annual general meeting.

Cathrin is a Special Partner at Vitruvian Partners LLP and also serves as a Non Executive Director for the NHS (Strategic Health Authority for Greater London), a Non Executive Director for Circassia Ltd and an advisor to Merz Pharma GmBH

Between 2000 and 2010 Cathrin was a Healthcare Partner in Apex Partners LLP with responsibility for originating, executing, monitoring and exiting healthcare private equity investments with a specific focus on Life Science investments in the pharmaceutical and medical device arena. Her early career included Senior Associate and Research Analyst roles at Schroder Ventures Life Sciences and Schroders Investment Management.

“We are delighted to welcome Cathrin to the ICON Board,” commented Chairman, Dr. Bruce Given. “Her financial experience, coupled with her extensive expertise in the analysis of healthcare industry trends, strategies and financial performance will complement the strengths and talents of our existing board members.”

Notes to Editors:

About ICON plc:

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programmes that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,700 employees, operating from 71 offices in 39 countries.

ICON/ICLR-F



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs